JP2021523913A5 - - Google Patents
Info
- Publication number
- JP2021523913A5 JP2021523913A5 JP2020564167A JP2020564167A JP2021523913A5 JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5 JP 2020564167 A JP2020564167 A JP 2020564167A JP 2020564167 A JP2020564167 A JP 2020564167A JP 2021523913 A5 JP2021523913 A5 JP 2021523913A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023183225A JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862672299P | 2018-05-16 | 2018-05-16 | |
| US62/672,299 | 2018-05-16 | ||
| PCT/US2019/032582 WO2019222449A1 (en) | 2018-05-16 | 2019-05-16 | Protein binding nkg2d, cd16 and a fibroblast activation protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Division JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523913A JP2021523913A (ja) | 2021-09-09 |
| JP2021523913A5 true JP2021523913A5 (enExample) | 2022-05-20 |
| JP7494129B2 JP7494129B2 (ja) | 2024-06-03 |
Family
ID=68540990
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564167A Active JP7494129B2 (ja) | 2018-05-16 | 2019-05-16 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183225A Active JP7680514B2 (ja) | 2018-05-16 | 2023-10-25 | Ｎｋｇ２ｄ、ｃｄ１６、及び線維芽細胞活性化タンパク質と結合するタンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210363261A1 (enExample) |
| EP (1) | EP3793605A4 (enExample) |
| JP (2) | JP7494129B2 (enExample) |
| KR (1) | KR20210010508A (enExample) |
| CN (1) | CN112423788A (enExample) |
| AU (2) | AU2019271263A1 (enExample) |
| BR (1) | BR112020023299A2 (enExample) |
| CA (1) | CA3100234A1 (enExample) |
| MX (1) | MX2020012273A (enExample) |
| SG (1) | SG11202011139YA (enExample) |
| WO (1) | WO2019222449A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3579848T3 (da) | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| KR20240060739A (ko) | 2017-02-20 | 2024-05-08 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| SG11202007579TA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| JP7353576B2 (ja) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法 |
| EP3833385A4 (en) | 2018-08-08 | 2021-12-22 | Dragonfly Therapeutics, Inc. | PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN |
| EP3833392A4 (en) | 2018-08-08 | 2022-05-18 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN115836088A (zh) | 2020-05-06 | 2023-03-21 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和clec12a的蛋白质 |
| US20240115670A1 (en) | 2021-01-27 | 2024-04-11 | Georgetown University | Fibroblast activation protein modulation to alter immune cell migration and tumor infiltration |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| EP4448582A4 (en) * | 2022-01-11 | 2026-05-06 | Adimab Llc | CH3 VARIANT DOMAINS MODIFIED FOR PREFERENTIAL CH3 HETERODIMERIZATION, MULTI-SPECIFIC ANTIBODIES COMPRISING THEM, AND THEIR MANUFACTURING PROCESSES |
| EP4311557A1 (en) * | 2022-07-26 | 2024-01-31 | Oncomatryx Biopharma, S.L. | Fap-targeted antibody-drug conjugates |
| TW202540200A (zh) | 2023-12-01 | 2025-10-16 | 美商基利科學股份有限公司 | 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途 |
| WO2025244097A1 (ja) * | 2024-05-23 | 2025-11-27 | オプティアム・バイオテクノロジーズ株式会社 | 改良型抗ＦＡＰα－キメラ抗原受容体 |
| CN119265201A (zh) * | 2024-08-23 | 2025-01-07 | 中国人民解放军海军军医大学第一附属医院 | 编码基因、蛋白、表达il-15的nkg2dl-fap双靶点car-nk细胞及其构建方法和用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101300272B (zh) * | 2005-10-14 | 2013-09-18 | 依奈特制药公司 | 用于治疗增生性病症的组合物和方法 |
| DK2222706T4 (en) * | 2007-12-14 | 2016-11-21 | Novo Nordisk As | Antibodies that bind to NKG2D and its use |
| US9273136B2 (en) * | 2008-08-04 | 2016-03-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Fully human anti-human NKG2D monoclonal antibodies |
| TW201109438A (en) | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| PE20120630A1 (es) * | 2009-08-17 | 2012-05-26 | Roche Glycart Ag | Inmunoconjugados dirigidos |
| SG187746A1 (en) * | 2010-08-13 | 2013-03-28 | Roche Glycart Ag | Anti-fap antibodies and methods of use |
| JP6441079B2 (ja) * | 2011-12-19 | 2018-12-19 | シンイミューン ゲーエムベーハー | 二重特異性抗体分子 |
| GB201402006D0 (en) * | 2014-02-06 | 2014-03-26 | Oncomatryx Biopharma S L | Antibody-drug conjugates and immunotoxins |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| EP3313876B1 (en) * | 2015-06-23 | 2025-01-22 | Innate Pharma | Multispecific antigen binding proteins |
| WO2017124002A1 (en) * | 2016-01-13 | 2017-07-20 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| JP7082604B2 (ja) * | 2016-03-21 | 2022-06-08 | マレンゴ・セラピューティクス，インコーポレーテッド | 多重特異性および多機能性分子ならびにその使用 |
| JP2018035137A (ja) * | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ | 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用 |
| DK3579848T3 (da) * | 2017-02-08 | 2025-01-20 | Dragonfly Therapeutics Inc | Multispecifikke bindende proteiner til aktivering af naturlige dræberceller og terapeutiske anvendelser heraf til behandling af kræft |
| US20200216544A1 (en) * | 2017-08-16 | 2020-07-09 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1 |
-
2019
- 2019-05-16 MX MX2020012273A patent/MX2020012273A/es unknown
- 2019-05-16 KR KR1020207035733A patent/KR20210010508A/ko not_active Ceased
- 2019-05-16 AU AU2019271263A patent/AU2019271263A1/en not_active Abandoned
- 2019-05-16 SG SG11202011139YA patent/SG11202011139YA/en unknown
- 2019-05-16 CN CN201980047481.2A patent/CN112423788A/zh active Pending
- 2019-05-16 BR BR112020023299-8A patent/BR112020023299A2/pt unknown
- 2019-05-16 CA CA3100234A patent/CA3100234A1/en active Pending
- 2019-05-16 US US17/055,792 patent/US20210363261A1/en not_active Abandoned
- 2019-05-16 JP JP2020564167A patent/JP7494129B2/ja active Active
- 2019-05-16 WO PCT/US2019/032582 patent/WO2019222449A1/en not_active Ceased
- 2019-05-16 EP EP19803947.1A patent/EP3793605A4/en active Pending
-
2023
- 2023-10-25 JP JP2023183225A patent/JP7680514B2/ja active Active
-
2026
- 2026-02-26 AU AU2026201454A patent/AU2026201454A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023509448A5 (enExample) | ||
| JP2021534096A5 (enExample) | ||
| JP2025111463A5 (enExample) | ||
| JP2020522474A5 (enExample) | ||
| JP2022061993A5 (enExample) | ||
| JP2021035388A5 (ja) | Ｃａｉｘ、ａｎｏ１、メソテリン、ｔｒｏｐ２またはクローディン−１８．２を標的にする多重特異性結合タンパク質 | |
| JP2020510653A5 (ja) | Ｃｅａを標的にする多重特異性結合タンパク質 | |
| JP2023123726A5 (enExample) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| JP2020521448A5 (enExample) | ||
| JP2019536430A5 (enExample) | ||
| JP2022507487A5 (enExample) | ||
| JP2020508997A5 (enExample) | ||
| JP2021522162A5 (enExample) | ||
| JP2021533159A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2023516004A5 (enExample) | ||
| JP2018507188A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2021522347A5 (enExample) | ||
| JP2022513043A5 (enExample) | ||
| RU2019129511A (ru) | Белки, связывающие gd2, nkg2d и cd16 | |
| JP2024504390A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2024532489A5 (enExample) |